Former CEO & Chairman “Pete” Petit Nominates Two Highly Qualified Professionals and Shareholders and Himself to the Board of MiMedx Group, Inc.
MARIETTA, Ga.--(BUSINESS WIRE)--Apr 11, 2019--Parker H. “Pete” Petit (“Mr. Petit”) today announced that he has nominated David J. Furstenberg (“Mr. Furstenberg”), Shawn P. George (“Mr. George”) and himself for election to the Board of Directors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (OTC: MDXG) at the Company’s upcoming Annual Meeting of Shareholders expected to be held on June 17, 2019. Mr. Petit, together with Mr. George and Mr. Furstenberg, are the beneficial owners of 4.3% of the common stock of MiMedx.
Mr. Petit, the former Chairman of the Board and CEO from 2009 to 2018, said, “In my opinion, the current Board has done a major disservice to MiMedx’s shareholders and there is no sign the Board has the ability, judgment or commitment to return MiMedx to its former growth and profitability as a NASDAQ listed company. Shareholders have been left in the dark while the Company’s value has significantly dropped. I could no longer sit on the sidelines. Together with Shawn and David, we, if elected, will bring a wealth of experience working on and resolving expeditiously highly contentious and complicated matters. I believe that our slate of candidates will instill the much needed accountability and reason in the boardroom that MiMedx is now lacking, while supporting its valuable employees and expanding its best in class intellectual property patents.”
For information about this campaign to bring much needed change to MiMedx’s current Board and thoughts on how we will seek to restore the Company’s lost value, please visit MiMedxBoardProxy.com.
- Parker H. “Pete” Petit is the current President of the Petit Group and the former Chairman of the Board and Chief Executive Officer of MiMedx. During Pete’s tenure as head of MiMedx, MiMedx grew from a start up to the 5 th fastest growing public company in 2017 according to Fortune magazine. Prior to Pete’s roles beginning in 2009 as Chairman and CEO of MiMedx, he was the Chairman and CEO of Matria Healthcare, Inc. (NASDAQ: MATR) from 1996 until it was sold in May 2008. Before then, Pete founded his own company, Healthdyne, Inc., in 1971 which grew to become three different public companies. Pete received his B.S. in Mechanical Engineering and his Master of Science degree in Engineering Mechanics from the Georgia Institute of Technology, and his M.B.A. in Finance from Georgia State University.
- David J. Furstenberg is the former Director of Taxes at Pulte Home Corporation, a Fortune 500 publicly traded homebuilder, a position he held from 1997 until his retirement in 2016. In his position, David led the federal, state and international tax research and planning functions as well as advised and partnered with executive management and multiple departments on tax matters related to M&A and other strategic initiatives. David is a certified public accountant and attorney and a member of the Michigan Association of CPAs and the State Bar of Michigan. David received his J.D. from Wayne State University Law School and his B.A. in Accounting from Michigan State University.
- Shawn P. George is a Partner at George & Lorensen, PLLC, a position he has held since the firm was founded in 1991. Shawn’s practice has spanned over thirty-seven years and includes both plaintiff and defense side representation in complex civil litigation and commercial matters. Shawn serves regularly as a counsel and consultant to businesses on a variety of corporate issues, including multi-forum litigation and risk related management, as well as an arbitrator or meditator in complex, multi-party business or commercial transactions and disputes. Shawn is recognized as a West Virginia Super Lawyer. Shawn received his J.D. from Washington and Lee University School of Law and his B.A. in Government from Hamilton College.
Schulte Roth & Zabel LLP is providing legal counsel to Mr. Petit.
Parker H. “Pete” Petit, David J. Furstenberg, and Shawn P. George (collectively, the “Nominees” or the “Participants”) intend to file with the SEC a definitive proxy statement and accompanying form of proxy to be used in connection with the solicitation of proxies from the stockholders of MiMedx. All shareholders of MiMedx are advised to read the definitive proxy statement and other documents related to the solicitation of proxies by the Participants when they become available, as they will contain important information, including additional information related to the Participants. The definitive proxy statement and an accompanying proxy card will be furnished to some or all of the Company’s shareholders and will be, along with other relevant documents, available at no charge on the SEC website at http://www.sec.gov/.
Information about the Participants and a description of their direct or indirect interests by security holdings is contained in the Schedule 14A filed by Mr. Petit with the SEC on April 11, 2019. This document is available free of charge from the sources indicated above.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190411005683/en/
The Dilenschneider Group
KEYWORD: UNITED STATES NORTH AMERICA GEORGIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL COMMUNICATIONS PUBLIC RELATIONS/INVESTOR RELATIONS GENERAL HEALTH
SOURCE: The Dilenschneider Group on behalf of MiMedx Shareholder Group
Copyright Business Wire 2019.
PUB: 04/11/2019 12:42 PM/DISC: 04/11/2019 12:42 PM